Otsuka (OTCMKTS:OTSKY) Stock Rating Upgraded by Zacks Research

Otsuka (OTCMKTS:OTSKY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other brokerages also recently commented on OTSKY. UBS Group upgraded shares of Otsuka to a “hold” rating in a research note on Tuesday, January 27th. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. Finally, Morgan Stanley upgraded Otsuka to an “overweight” rating in a report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Otsuka currently has an average rating of “Hold”.

Otsuka Stock Up 2.9%

Shares of Otsuka stock opened at $36.39 on Tuesday. Otsuka has a 52-week low of $21.64 and a 52-week high of $36.55. The company has a 50 day moving average of $32.73 and a 200 day moving average of $29.65. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $39.09 billion and a P/E ratio of 15.82.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.